TScan Therapeutics, Inc. (TCRX)

Market Cap	219.89M
Revenue (ttm)	9.36M
Net Income (ttm)	-111.30M
Shares Out	53.37M
EPS (ttm)	-2.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	158,870
Open	4.190
Previous Close	4.210
Day's Range	4.030 - 4.230
52-Week Range	3.730 - 9.690
Beta	0.78
Analysts	Strong Buy
Price Target	11.40 (+176.7%)
Earnings Date	Nov 12, 2024

About TCRX

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 16, 2021
• Employees: 154
• Stock Exchange: NASDAQ
• Ticker Symbol: TCRX
• Website: https://www.tscan.com

Financial Performance

In 2023, TScan Therapeutics's revenue was $21.05 million, an increase of 55.52% compared to the previous year's $13.54 million. Losses were -$89.22 million, 34.7% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for TCRX stock is "Strong Buy." The 12-month stock price forecast is $11.4, which is an increase of 176.70% from the latest price.

Price Target

$11.4

(176.70% upside)

Analyst Consensus: Strong Buy